San Diego-primarily based Viking Therapeutics marked itself as a significant competitor during the weight loss drug current market in February just after revealing promising facts from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As